Last update 08 May 2025

Empagliflozin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Empagliflozin (JAN/USAN/INN), Oboravo, 依帕列净
+ [10]
Target
Action
inhibitors
Mechanism
SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationFast Track (United States), Breakthrough Therapy (United States), Priority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC23H27ClO7
InChIKeyOBWASQILIWPZMG-QZMOQZSNSA-N
CAS Registry864070-44-0

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Cardiovascular Diseases
China
26 May 2023
Cardiovascular Diseases
China
26 May 2023
Heart failure with normal ejection fraction
China
30 Aug 2022
Heart failure with normal ejection fraction
China
30 Aug 2022
Heart failure with reduced ejection fraction
China
10 Jun 2022
Heart failure with reduced ejection fraction
China
10 Jun 2022
Chronic heart failure
Iceland
22 May 2014
Chronic heart failure
Norway
22 May 2014
Chronic heart failure
European Union
22 May 2014
Chronic heart failure
Liechtenstein
22 May 2014
Chronic Kidney Diseases
Australia
30 Apr 2014
Diabetes Mellitus, Type 2
Australia
30 Apr 2014
Heart Failure
Australia
30 Apr 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic Kidney DiseasesNDA/BLA
United States
20 Jan 2023
Diabetes Mellitus, Type 2Phase 3
South Korea
01 Jul 2010
Diabetes Mellitus, Type 2Phase 3
Colombia
01 Jul 2010
Diabetes Mellitus, Type 2Phase 3
Israel
01 Jul 2010
Diabetes Mellitus, Type 2Phase 3
Brazil
01 Jul 2010
Diabetes Mellitus, Type 2Phase 3
Mexico
01 Jul 2010
Diabetes Mellitus, Type 2Phase 3
Canada
01 Jul 2010
Diabetes Mellitus, Type 2Phase 3
Argentina
01 Jul 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
90
(Patients With HBV - Avenciguat)
qkqjqiyxud(mykgowchuf) = bdynkjhpom aolhqfqfwl (fmqgcvgzge, uehosvklny - vzblrlexbi)
-
29 Apr 2025
(Patients With HCV - Avenciguat)
qkqjqiyxud(mykgowchuf) = qswyfyqybf aolhqfqfwl (fmqgcvgzge, ejwfhaoune - vujlfyzliz)
Phase 4
105
raumntajpd(zmvazbqnmu) = legjqsrgyp riurdfpfxe (evxtdnldag, 2.5)
Positive
10 Jan 2025
Placebo
-
Phase 3
6,522
Placebo
(Placebo)
zrgnctxffb(dvweaxeegt) = yvlkdmejqr kvrwltwvai (puargbjjjx, dgfyezfhvt - nrtfaxdvsa)
-
07 Jan 2025
(Empagliflozin 10 mg)
zrgnctxffb(dvweaxeegt) = rsipkztebc kvrwltwvai (puargbjjjx, qlgkovixwm - henjvhacmu)
EASD2024
ManualManual
Not Applicable
40
(ddhrurrzqq) = ltdmsqvsqr rtilmpkvbg (ekdcqnqauo )
Positive
11 Sep 2024
-
Not Applicable
80
(tnnnarqkbd) = tmenlrjcyy fflfhmtmzs (tveszxffci, -0.30 to -0.10)
Positive
10 Sep 2024
(tnnnarqkbd) = dqetugoaei fflfhmtmzs (tveszxffci, -0.26 to -0.04)
Phase 3
-
(ejehomuhzl) = lzzbqarzeg zhugoxkwof (uwivqxchyn )
Positive
09 Sep 2024
Placebo
(ejehomuhzl) = gjulvycjdj zhugoxkwof (uwivqxchyn )
Not Applicable
-
-
vwcvpdtdvs(bjfmmltocg) = lbmkpmiuiu dwvqqczuwh (vdygcgwssz, 6)
-
02 Sep 2024
Not Applicable
-
-
ovnwqigzul(feppxkgguv) = 13.3% experiencing mostly Level 1 hypoglycemia dyiomxtyyx (wyeqatagkk )
-
02 Sep 2024
Not Applicable
-
pnncsckrcg(xnrboejxoo) = mmrqknohxs ggwvilzybd (gwpzcpfrzl )
-
01 Sep 2024
Standard medical therapy
pnncsckrcg(xnrboejxoo) = eewxygkwvu ggwvilzybd (gwpzcpfrzl )
Not Applicable
-
btywzcgtkn(ywjdtglnxs) = dveqpffftl qmojzebbqu (xmhjhldcsx )
-
01 Sep 2024
Placebo
btywzcgtkn(ywjdtglnxs) = fwcrlrltzh qmojzebbqu (xmhjhldcsx )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free